Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573351 · ClinicalTrials.gov registry record · Phase 3
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
NCT01573351 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 398 participants.
The verdict
NCT01573351, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Asunaprevir
- DRUG Peg-interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573351
The ClinicalTrials.gov registry entry for NCT01573351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01573351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01573351 about?
NCT01573351 is a clinical study titled "Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)". The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12.
What is the current status of trial NCT01573351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2012-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01573351?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Asunaprevir (DRUG), Peg-interferon Alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01573351?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.